Abstract A097: Tubulysin ADC payloads: An antimitotic drug class that retains activity in multidrug resistant models
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a097
Abstract: As antibody-drug conjugates (ADCs) find increasing clinical application, treatment-related resistance mechanisms may eventually impact efficacy. One resistance mechanism that emerges following prolonged exposure to auristatin-based ADCs such as brentuximab vedotin and polatuzumab vedotin involves upregulation… read more here.
Keywords: drug; resistant models; adc payloads; activity ... See more keywords
IN VIVO SYNGENEIC TUMOR MODELS WITH ACQUIRED RESISTANCE TO ANTI-PD-1/PD-L1 THERAPIES.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-0802
Abstract: Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of cancer patients. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this… read more here.
Keywords: acquired resistance; resistant models; resistance anti; resistance ... See more keywords